Inhibition of the binding of HCV serum particles to human hepatocytes by E1E2-specific D32.10 monoclonal antibody

Journal of Medical Virology

Volumn 81, Issue 10, 2009, Pages 1726-1733

  Ndongo, Ndiémé ^a,b   Rechoum, Yassine ^c   De Sequeira, Sylvie ^a,b   Zoulim, Fabien ^a,b,d   Trépo, Christian ^a,b,d   Drouet, Emmanuel ^c   Petit, Marie Anne ^a,b  

^a INSERM   (France)

^b UNIVERSITÉ LYON 1   (France)

^c UNIV GRENOBLE ALPES   (France)

^d HÔTEL DIEU   (France)

Author keywords

Anti E1E2 monoclonal antibody; Cell binding assays; Hepatitis C virus; Human hepatocytes; Serum particles

Indexed keywords

EPITOPE; LIGAND; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY D32.10; RECEPTOR; UNCLASSIFIED DRUG; VIRUS RNA;

ANTIBODY SPECIFICITY; ARTICLE; BINDING AFFINITY; BINDING ASSAY; BINDING SITE; CELL INTERACTION; CELL PROLIFERATION; CONCENTRATION RESPONSE; GENOTYPE; HEPATITIS C VIRUS; HUMAN; HUMAN CELL; IC 50; IN VITRO STUDY; ISOTOPE LABELING; LIVER CELL; REAL TIME POLYMERASE CHAIN REACTION; RECEPTOR BINDING; SCATCHARD PLOT; VIRUS ATTACHMENT; VIRUS PARTICLE;

ANTIBODIES, MONOCLONAL; CELL LINE; HEPACIVIRUS; HEPATITIS C ANTIBODIES; HEPATOCYTES; HUMANS; INHIBITORY CONCENTRATION 50; VIRAL ENVELOPE PROTEINS; VIRUS ATTACHMENT;

HEPATITIS C VIRUS;

EID: 69949159251     PISSN: 01466615     EISSN: 10969071     Source Type: Journal    
DOI: 10.1002/jmv.21562     Document Type: Article

References (29)

1. Bartosch B, Dubuisson J, Cosset FL. 2003. Infectious hepatitis C virus pseudo-particles containing functional E1-E2 envelope protein complexes. J Exp Med 197:633-642. (Pubitemid 36314658)
2. Bartosch B, Vitelli A, Granier C, Goujon C, Dubuisson J, Pascale S, Scarselli E, Cortese R, Nicosia A, Cosset FL. 2003. Cell entry of hepatitis C virus requires a set of co-receptors that include the CD81 tetraspanin and the SR-B1 scavenger receptor. J Biol Chem 278:41624-41630. (Pubitemid 37310418)
3. Baumert TF, Ito S, Wong DT, Liang TJ. 1998. Hepatitis C virus structural proteins assemble into viruslike particles in insect cells. J Virol 72:3827-3836. (Pubitemid 28188682)
4. Brazzoli M, Bianchi A, Filippini S, Zhu Q, Pizza M, Crotta S. 2008. CD81 is a central regulator of cellular events required for HCV infection of human hepatocytes. J Virol 82:8316-8329.
5. Chisari FV. 2005. Unscrambling hepatitis C virus-host interactions. Nature 436:930-942.
6. Dubuisson J, Helle F, Cocquerel L. 2008. Early steps of the hepatitis C virus life cycle. Cell Microbiol 10:821-827.
7. Feld JJ, Hoofnagle JH. 2005. Mechanism of action of interferon and ribavirin in treatment of hepatitis C. Nature 436:967-972. (Pubitemid 41191673)
8. Foy E, Li K, Sumpter R, Jr., Loo YM, Johnson CL, Wang C, Fish PM, Yoneyama M, Fujita T, Lemon SM, Gale M, Jr. 2005. Control of antiviral defenses through hepatitis C virus disruption of retinoic acid-inducible gene-I signaling. Proc Natl Acad Sci USA 102:2986-2991.
9. Germi R, Crance JM, Garin D, Guimet J, Lortat-Jacob H, Ruigrok RWH, Zarski JP, Drouet E. 2002. Cellular glycosaminoglycans and low density lipoprotein receptor are involved in hepatitis C virus adsorption. J Med Virol 68:206-215. (Pubitemid 34936726)
10. Godard A, Heymann D, Raher S, Anegon I, Peyrat MA, Le Mauff B, Mouray E, Gregoire M, Virdee K, Soulillou JP, Moreau F, Jacques Y. 1992. High and low affinity receptors for human interleukin for DA cells/leukemia inhibitory factor on human cells. J Biol Chem 267:3214-3222.
11. Hsu M, Zhang J, Flint M, Logvinoff C, Cheng-Mayer C, Rice CM, McKeating JA. 2003. Hepatitis C virus glycoproteins mediate pH-dependent cell entry of pseudotyped retroviral particles. Proc Natl Acad Sci USA 100:7271-7276. (Pubitemid 36706428)
12. Law M, Maruyama T, Lewis J, Giang E, Tarr AW, Stamataki Z, Gastaminza P, Chisari FV, Jones IM, Fox RI, Ball JK, McKeating JA, Kneteman NM, Burton DR. 2008. Broadly neutralizing antibodies protect against hepatitis C virus quasispecies challenge. Nat Med 14:25-27.
13. Lindenbach BD, Evans MJ, Syder AJ, Wölk B, Tellinghuisen TL, Liu CC, Maruyama T, Hynes RO, Burton DR, McKeating JA, Rice CM. 2005. Complete replication of hepatitis C virus in cell culture. Science 309:623-626. (Pubitemid 41033648)
14. Lindenbach BD, Thiel HJ, Rice CM. 2007. Flaviviridae: The viruses and their replication. In: Knipe DM, Howley PM, editors. Fields virology. 5th edition. Philadelphia: Lippincott-Raven Publishers.
15. Maire M, Parent R, Morand AL, Alotte C, Trépo C, Durantel D, Petit MA. 2008. Characterization of the double-stranded RNA responses in human liver progenitor cells. Biochem Biophys Res Commun 368:556-562.
16. Meunier JC, Russell RS, Goossens V, Priem S, Walter H, Depla E, Union A, Faulk KN, Bukh J, Emerson SU, Purcell RH. 2008. Isolation and characterization of broadly neutralizing human monoclonal antibodies to the E1 glycoprotein of hepatitis C virus. J Virol 82:966-973.
17. Molina S, Castet V, Pichard-Garcia L, Wychowski C, Meurs E, Pascussi JM, Sureau C, Fabre JM, Sacunha A, Larrey D, Dubuisson J, Coste J, McKeating JA, Maurel P, Fournier-Wirth C. 2008. Serum-derived hepatitis C virus infection of primary human hepatocytes is tetraspanin CD81 dependent. J Virol 82:569-574. (Pubitemid 350309172)
18. Olenina LV, Kuzmina TI, Sobolev BN, Kuraeva TE, Kolesanova EF, Archakov AI. 2005. Identification of glycosaminoglycan-binding sites within hepatitis C virus envelope glycoprotein E2. J Viral Hepat 12:584-593. (Pubitemid 41532489)
19. Parent R, Marion MJ, Furio L, Trépo C, Petit MA. 2004. Origin and characterization of a human bipotent liver progenitor cell line. Gastroenterology 126:1147-1156. (Pubitemid 38451185)
20. Petit MA, Jolivet-Reynaud C, Peronnet E, Michal Y, Trépo C. 2003. Mapping of a conformational epitope shared between E1 and E2 on the serum-derived human hepatitis C virus envelope. J Biol Chem 278:44385-44392. (Pubitemid 37377187)
21. Petit MA, Lièvre M, Peyrol S, De Sequeira S, Berthillon P, Ruigrok RWH, Trépo C. 2005. Enveloped particles in the serum of chronic hepatitis C patients. Virology 336:144-153. (Pubitemid 40693949)
22. Rothwangl KB, Manicassamy B, Uprichard SL, Rong L. 2008. Dissecting the role of putative CD81 binding regions of E2 in mediating HCV entry: Putative CD81 binding region I is not involved in CD81 binding. Virol J 5:46-58.
23. Tarr AW, Owsianka AM, Timms JM, McClure CP, Brown RJP, Hickling TP, Pietschmann T, Bartenschlager R, Patel AH, Ball JK. 2006. Characterization of the hepatitis C virus E2 epitope defined by the broadly neutralizing monoclonal antibody AP33. Hepatology 43:592-601.
24. Tejedor F, Ballesta JP. 1982. Iodination of biological samples without loss of functional activity. Anal Biochem 127:143-149. (Pubitemid 13155100)
25. Triyatni M, Saunier B, Maruvada P, Davis AR, Ulianich L, Heller T, Patel A, Kohn LD, Liang TJ. 2002. Interaction of hepatitis C virus-like particles and cells: A model system for studying viral binding and entry. J Virol 76:9335-9344. (Pubitemid 34919891)
26. Wakita T, Pietschmann T, Kato T, Date T, Myamoto M, Zhao Z, Murthy K, Habermann A, Krausslich HG, Mizokami M, Bartenschlager R, Liang TJ. 2005. Production of infectious hepatitis C virus in tissue culture from a cloned viral genome. Nat Med 11:791-796. (Pubitemid 41021213)
27. Wellnitz S, Klumpp B, Bart H, Ito S, Depla E, Dubuisson J, Blum HE, Baumert TF. 2002. Binding of hepatitis C virus-like particles derived from infectious clone H77C to defined human cell lines. J Virol 76:1181-1193. (Pubitemid 34066422)
28. Yagnik AT, Lahm A, Meola A, Roccasecca RM, Ercole BB, Nicosia A, Tramontano A. 2000. A model for the hepatitis C virus envelope glycoprotein E2. Proteins 40:355-366. (Pubitemid 30624444)
29. Zhong J, Gastaminza P, Cheng G, Kapadia S, Kato T, Burton DR, Wieland SF, Uprichard SL, Wakita T, Chisari FV. 2005. Robust hepatitis C virus infection in vitro. Proc Natl Acad Sci USA 102:9294-9299. (Pubitemid 40923557)